All news

Spineway’s Board of Directors, at a meeting held on 25 January 2021 chaired by Stéphane Le Roux, closed the 2020 annual accounts.

Spineway, specialized in innovative implants for the treatment of disorders of the spinal column (spine), showed a sharp increase in sales for the month of December 2020 (+30% compared with December 2019), allowing it to post revenue of €1 068K for the fourth quarter, up 21% compared with the third quarter of 2020. This positive dynamism brough the Group’s annual revenue to €3 380K and decreased the gap with 2019 (-33%) for a year that was deeply affected by the COVID crisis.

SPINEWAY (ISIN : FR0011398874 – ALSPW), specialized in the treatment of severe disorders of the spine, announced today its 2021 financial calendar.

In keeping with its development strategy, Spineway wishes to be in a position to take advantage of any and all external-growth opportunities that could create value and new synergies. To this end, Spineway decided to launch a new subscription phase for Convertible Bonds with warrants.

Spineway, specialized in innovative implants for the treatment of severe disorders of the spinal column (spine), announces its choice of TUV Rheinland as the notified body for the certification of its implant and instrument product lines. With the European regulations governing medical devices constantly changing and ever more stringent, Spineway thus ensures that it will be able to provide high-quality products consistently.

Le Conseil d’Administration de Spineway, réuni le 26 Octobre 2020 sous la Présidence de Stéphane Le Roux, a arrêté les comptes semestriels 2020.

Spineway, specialized in the treatment of severe disorders of the spine, announces the launch of a new concept: MISTI (acronym for Minimally Invasive Spine Total Instrumentation).

Spineway, specialized in the treatment of severe disorders of the spine, announces the publication of a scientific article in the renowned scientific journal Spine Deformity1 highlighting the benefits of the Mont-Blanc 3D+ technology for the treatment of adolescent idiopathic scoliosis.

The first half of this year was understandably affected by the health crisis caused by the worldwide Coronavirus pandemic, which led to the cancellation of all non-essential surgeries. During this unprecedented period, the Spineway group was fully committed to providing the best possible services to its direct clients in France and its international distribution partners. These efforts allowed the Group to keep its revenue for the second quarter at close to 30% of that of the previous year despite a very complicated international situation, resulting in half-year revenue of €1 432K as at 30 June 2020 (-45% compared with HY1 2019)